title: Comparison of montelukast and mometasone furoate in the prevention of recurrent nasal polyps.
abstract: BACKGROUND
  The aim of our study was to compare the effects of montelukast and mometasone furoate nasal spray on the postoperative course of patients with nasal polyposis.
  
  
  METHODS
  Fifty patients diagnosed with nasal polyposis between March 2006 and August 2007 were included in the study. All patients underwent bilateral endoscopic sphenoethmoidectomy and were randomized postoperatively into two groups. Group A (n = 25) received 10 mg montelukast per day and group B (n = 25) received 400 µg mometasone furoate nasal spray twice daily. All patients were followed up for 6 months. Sino-Nasal Outcome Test (SNOT)-22 scores, polyp grades, computerized tomography (CT) scores (Lund-Mackay), eosinophils in peripheral blood and polyp tissue were evaluated before and after surgery.
  
  
  RESULTS
  There was a significant reduction in SNOT-22 scores in both groups throughout the study period. There was a significant difference in the recurrence rate between both groups with a marginal advantage of mometasone furoate nasal spray. Eosinophils in peripheral blood were found to be effective on the recurrence rate (p < 0.05).
  
  
  CONCLUSIONS
  In conclusion, both drugs seem to have a complementary action and further studies are needed to determine which patients should receive which treatment.
authors: Department of Otorhinolaryngology Clinic, Trabzon Numune Research and Training Hospital, Trabzon, Turkey. erkanvuralkan@ hotmail.com
authors: Erkan
authors: E
authors: Vuralkan
authors: Cem
authors: C
authors: Saka
authors: Istemihan
authors: I
authors: Akin
authors: Sema
authors: S
authors: Hucumenoglu
authors: Binnur Uzmez
authors: BU
authors: Unal
authors: Gokhan
authors: G
authors: Kuran
authors: Berrak
authors: B
authors: Ocal
mesh_terms: D000085:Acetates / Q000008:administration & dosage / Q000627:therapeutic use*; D000281:Administration, Intranasal; D000328:Adult; D000368:Aged; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D003521:Cyclopropanes; D004724:Endoscopy / Q000379:methods; D004804:Eosinophils / Q000378:metabolism; D005005:Ethmoid Sinus / Q000601:surgery; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D020024:Leukotriene Antagonists / Q000008:administration & dosage / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D000068656:Mometasone Furoate; D009298:Nasal Polyps / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery; D059085:Nasal Sprays; D011244:Pregnadienediols / Q000008:administration & dosage / Q000627:therapeutic use*; D011446:Prospective Studies; D011804:Quinolines / Q000008:administration & dosage / Q000627:therapeutic use*; D055502:Secondary Prevention; D013101:Sphenoid Sinus / Q000601:surgery; D013440:Sulfides; D014057:Tomography, X-Ray Computed; D016896:Treatment Outcome
chemical_list: D000085:Acetates; D000893:Anti-Inflammatory Agents; D003521:Cyclopropanes; D020024:Leukotriene Antagonists; D059085:Nasal Sprays; D011244:Pregnadienediols; D011804:Quinolines; D013440:Sulfides; D000068656:Mometasone Furoate; C093875:montelukast